Clinical Trials Browser

Phase 1/2 × Lymphoma, Extranodal NK-T-Cell × tislelizumab × Clear all

NCT07502768 2026-03-31

EpiRev-NKT

Phase 1/2 Not yet recruiting

Recurrence, Lymphoma, Extranodal NK-T-Cell

NCT04425070 2026-01-05

TOUCH

Phase 1/2 Terminated

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell